scholarly journals Efficacy of Magnesium Trihydrate of Ursodeoxycholic Acid and Chenodeoxycholic Acid for Gallstone Dissolution: A Prospective Multicenter Trial

Gut and Liver ◽  
2015 ◽  
Vol 9 (4) ◽  
pp. 547 ◽  
Author(s):  
Jong Jin Hyun ◽  
Hong Sik Lee ◽  
Chang Duck Kim ◽  
Seok Ho Dong ◽  
Seung-Ok Lee ◽  
...  
Keyword(s):  
Ursodeoxycholic Acid ◽  
Chenodeoxycholic Acid ◽  
Multicenter Trial ◽  
Gallstone Dissolution ◽  
Prospective Multicenter Trial

Lichen planus associated with chenodeoxycholic acid and ursodeoxycholic acid for gallstone dissolution

1992 ◽  
Vol 37 (4) ◽  
pp. 628-630 ◽  
Author(s):  
Joseph P. M. Ellul ◽  
Richard Groves ◽  
Julian R. F. Walters ◽  
Gerard M. Murphy
Keyword(s):  
Ursodeoxycholic Acid ◽  
Lichen Planus ◽  
Chenodeoxycholic Acid ◽  
Gallstone Dissolution

Rowachol for gallstone dissolution?

1985 ◽  
Vol 23 (19) ◽  
pp. 75-76
Keyword(s):  
Combination Therapy ◽  
Ursodeoxycholic Acid ◽  
Chenodeoxycholic Acid ◽  
Common Duct ◽  
Cholesterol Gallstones ◽  
Gallstone Dissolution ◽  
The Common

Rowachol (Tillotts) is a mixture of monoterpenes intended for the dissolution of cholesterol gallstones, as an adjunct to the existing drugs chenodeoxycholic acid (CDCA) and ursodeoxycholic acid (UDCA) whose use we discussed last month.1 When combined with CDCA, Rowachol is claimed to dissolve stones in the common duct. This article assesses its efficacy both alone and in combination therapy.

103: Minimal Invasive Treatment of Men with Cathegory IIIB (CPPS) Prostatitis. A Prospective Multicenter Trial: Results of the MICP Study

2007 ◽  
Vol 177 (4S) ◽  
pp. 36-36
Author(s):  
Bob Djavan ◽  
Christian Seitz ◽  
Martina Nowak ◽  
Michael Dobrovits ◽  
Mike Harik ◽  
...  
Keyword(s):  
Multicenter Trial ◽  
Minimal Invasive ◽  
Invasive Treatment ◽  
Minimal Invasive Treatment ◽  
Prospective Multicenter Trial

Endovenous radiofrequency powered segmental thermal ablation (Closure FAST) of great saphenous veins

Phlebologie ◽  
2010 ◽  
Vol 39 (02) ◽  
pp. 69-71 ◽  
Author(s):  
T. M. Proebstle ◽  
Keyword(s):  
Side Effects ◽  
Thermal Ablation ◽  
Clinical Success ◽  
Clinical Success Rate ◽  
Duplex Ultrasound ◽  
Multicenter Trial ◽  
Saphenous Veins ◽  
Clinical Control ◽  
Prospective Multicenter Trial

Summary Background: Radiofrequency powered segmental thermal ablation Closure FAST has become a globally engaged technology for ablation of incompetent great saphenous veins (GSVs). Mid-term results of slowly resolving side effects are still not described. Methods: RSTA-treated GSVs (n = 295) were followed for 24 months in a prospective multicenter trial. Clinical control visits included flow and reflux analysis by duplex-ultrasound and assessment of treatment related side effects at all times. Results: 280 of 295 treated GSVs (94.9%) were available for 24 months follow-up. According to the method of Kaplan and Meier at 24 months after the intervention 98.6% of treated legs remained free of clinically relevant axial reflux. The average VCSS score improved from 3.9 ± 2.1 at screening to 0.7 ± 1.2 at 24 months follow-up (p < 0.0001). While only 41.1% of patients were free of pain before treatment, at 24 months 99.3% reported no pain and 96.4% did not experience pain during the 12 months before. At 24 months n=3 legs showed pigmentation along the inner thigh and one leg showed study-treatment related paresthesia. Conclusion: Radiofrequency powered segmental thermal ablation Closure FAST showed a very moderate side-effect profile in conjunction with a high and durable clinical success rate.

Sign in / Sign up

Export Citation Format

Share Document